Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Sun Pharma launches first branded ophthalmic product BromSite in US

Developed by its California-based subsidiary, InSite Vision, the product is also the first bromfenac ophthalmic solution formulated in DuraSite, a polymer-based drug delivery system

BS B2B Bureau  |  Mumbai 

Sun Pharma launches first branded ophthalmic product BromSite in US

has launched its first branded product, (bromfenac solution) 0.075%, in the US market. A non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of post-operative inflammation and prevention of pain in patients undergoing surgery, will be marketed by Sun Ophthalmics, the company’s branded business division.  
 
Approved by the on April 8, 2016, is the first NSAID approved to prevent pain and treat inflammation in the eye following surgery. Developed by California-based InSite Vision, a subsidiary of Sun Pharma, it is also the first bromfenac solution formulated in DuraSite, a polymer-based drug delivery system that is used to improve drug solubility, absorption, bioavailability, and residence time as compared to conventional topical therapies.

“As the first branded product launched by Sun Ophthalmics business division, BromSite’s launch is a significant milestone for in the US. We are confident will prove itself a quality treatment option for surgeons and their patients. Furthermore, with several promising candidates in our ophthalmics pipeline, Sun Ophthalmics is positioned to provide eye care professionals additional, quality treatment options in the near future,” commented Abhay Gandhi, CEO - North America Business,

Jerry St. Peter, vice president & head - Sun Ophthalmics, added, “This is an exciting, important moment for Sun Ophthalmics. The launch marks not only the unveiling of our first brand, but the entry of a new, robust sales force and marketing team dedicated to optimal customer service. We are committed to providing products that enhance doctors’ practice patterns and treatment options, as well as delivering these products through a talented, knowledgeable, and responsive commercial team. is our first opportunity to prove that commitment to eye care professionals.”

RECOMMENDED FOR YOU

Sun Pharma launches first branded ophthalmic product BromSite in US

Developed by its California-based subsidiary, InSite Vision, the product is also the first bromfenac ophthalmic solution formulated in DuraSite, a polymer-based drug delivery system

Developed by its California-based subsidiary, InSite Vision, the product is also the first bromfenac ophthalmic solution formulated in DuraSite, a polymer-based drug delivery system
has launched its first branded product, (bromfenac solution) 0.075%, in the US market. A non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of post-operative inflammation and prevention of pain in patients undergoing surgery, will be marketed by Sun Ophthalmics, the company’s branded business division.  
 
Approved by the on April 8, 2016, is the first NSAID approved to prevent pain and treat inflammation in the eye following surgery. Developed by California-based InSite Vision, a subsidiary of Sun Pharma, it is also the first bromfenac solution formulated in DuraSite, a polymer-based drug delivery system that is used to improve drug solubility, absorption, bioavailability, and residence time as compared to conventional topical therapies.

“As the first branded product launched by Sun Ophthalmics business division, BromSite’s launch is a significant milestone for in the US. We are confident will prove itself a quality treatment option for surgeons and their patients. Furthermore, with several promising candidates in our ophthalmics pipeline, Sun Ophthalmics is positioned to provide eye care professionals additional, quality treatment options in the near future,” commented Abhay Gandhi, CEO - North America Business,

Jerry St. Peter, vice president & head - Sun Ophthalmics, added, “This is an exciting, important moment for Sun Ophthalmics. The launch marks not only the unveiling of our first brand, but the entry of a new, robust sales force and marketing team dedicated to optimal customer service. We are committed to providing products that enhance doctors’ practice patterns and treatment options, as well as delivering these products through a talented, knowledgeable, and responsive commercial team. is our first opportunity to prove that commitment to eye care professionals.”

image
Business Standard
177 22

Sun Pharma launches first branded ophthalmic product BromSite in US

Developed by its California-based subsidiary, InSite Vision, the product is also the first bromfenac ophthalmic solution formulated in DuraSite, a polymer-based drug delivery system

has launched its first branded product, (bromfenac solution) 0.075%, in the US market. A non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of post-operative inflammation and prevention of pain in patients undergoing surgery, will be marketed by Sun Ophthalmics, the company’s branded business division.  
 
Approved by the on April 8, 2016, is the first NSAID approved to prevent pain and treat inflammation in the eye following surgery. Developed by California-based InSite Vision, a subsidiary of Sun Pharma, it is also the first bromfenac solution formulated in DuraSite, a polymer-based drug delivery system that is used to improve drug solubility, absorption, bioavailability, and residence time as compared to conventional topical therapies.

“As the first branded product launched by Sun Ophthalmics business division, BromSite’s launch is a significant milestone for in the US. We are confident will prove itself a quality treatment option for surgeons and their patients. Furthermore, with several promising candidates in our ophthalmics pipeline, Sun Ophthalmics is positioned to provide eye care professionals additional, quality treatment options in the near future,” commented Abhay Gandhi, CEO - North America Business,

Jerry St. Peter, vice president & head - Sun Ophthalmics, added, “This is an exciting, important moment for Sun Ophthalmics. The launch marks not only the unveiling of our first brand, but the entry of a new, robust sales force and marketing team dedicated to optimal customer service. We are committed to providing products that enhance doctors’ practice patterns and treatment options, as well as delivering these products through a talented, knowledgeable, and responsive commercial team. is our first opportunity to prove that commitment to eye care professionals.”

image
Business Standard
177 22